Cholangiocarcinoma:The era of liquid biopsy  

作　　者：Evgenia Kotsifa Francesca Saffioti Vasileios K Mavroeidis 

机构地区：[1]The Second Propaedeutic Department of Surgery,National and Kapodistrian University of Athens,General Hospital of Athens“Laiko”,Athens 11527,Greece [2]Department of Gastroenterology and Hepatology,Oxford University Hospitals NHS Foundation Trust,Oxford OX39DU,United Kingdom [3]University College London Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit,Royal Free Hospital and University College London,London NW32QG,United Kingdom [4]Division of Clinical and Molecular Hepatology,Department of Clinical and Experimental Medicine,University Hospital of Messina,Messina 98124,Italy [5]Department of Transplant Surgery,North Bristol NHS Trust,Southmead Hospital,Bristol BS105NB,United Kingdom [6]Department of Gastrointestinal Surgery,North Bristol NHS Trust,Southmead Hospital,Bristol BS105NB,United Kingdom [7]Department of HPB Surgery,Bristol Royal Infirmary,University Hospitals Bristol and Weston NHS Foundation Trust,Bristol BS28HW,United Kingdom

出　　处：《World Journal of Gastroenterology》2025年第11期14-32,共19页世界胃肠病学杂志(英文)

摘　　要：Cholangiocarcinoma(CCA)is a highly aggressive and heterogeneous malignancy arising from the epithelial cells of the biliary tract.The limitations of the current methods in the diagnosis of CCA highlight the urgent need for new,accurate tools for early cancer detection,better prognostication and patient monitoring.Liquid biopsy(LB)is a modern and non-invasive technique comprising a diverse group of methodologies aiming to detect tumour biomarkers from body fluids.These biomarkers include circulating tumour cells,cell-free DNA,circulating tumour DNA,RNA and extracellular vesicles.The aim of this review is to explore the current and potential future applications of LB in CCA management,with a focus on diagnosis,prognostication and monitoring.We examine both its significant potential and the inevitable limitations associated with this technology.We conclude that LB holds considerable promise,but further research is necessary to fully integrate it into precision oncology for CCA.

关 键 词：Biliary tract cancer CHOLANGIOCARCINOMA Circulating tumour cells Cell free DNA Circulating tumour DNA Circulating RNA Biomarkers Extracellular vesicles Precision medicine 

分 类 号：R73[医药卫生—肿瘤]